Skip to main content
Fig. 3 | BMC Immunology

Fig. 3

From: Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV

Fig. 3

Observed VRC07-523LS concentrations with 90% prediction interval from the base popPK model. Symbols and colors represent the observed concentrations from different dosing regimens with circles indicating those after intravenous administration and triangles indicating those after subcutaneous administration. Solid lines represent the predicted median concentration of each study regimen, with shaded areas denoting the 90% prediction interval

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us